Specifically, BARDA supports the advanced development and procurement of drugs, vaccines, and other products that are considered priorities for responding to and recovering from threats to ...
H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in ...
Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the ...
Learn more about a recompete NIH contract awarded to the Alliance for Advancing Biomedical Research to operate NCI's ...
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a C ...
Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...